Clinical Value of a 51-Neuroendocrine Tumor–Specific Gene Signature (NETest 2.0) for Management of Pancreatic and Small Bowel Neuroendocrine Tumors: A Prospective Study in a Consecutive Cohort of 82 Patients Considered for Surgery
- DOI
- 10.1097/as9.0000000000000700
- Published
- 2026-08-10
- Container
- Annals of Surgery Open
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1097/as9.0000000000000700,
title = {Clinical Value of a 51-Neuroendocrine Tumor–Specific Gene Signature (NETest 2.0) for Management of Pancreatic and Small Bowel Neuroendocrine Tumors: A Prospective Study in a Consecutive Cohort of 82 Patients Considered for Surgery},
author = {Andrea Frilling and Ashley Clift and Duncan Spalding and Panagiotis Drymousis and Alexander von Roon and Robert Goldin and Jamshed Bomanji and Harpreet Wasa and Abdel B. Halim and Mark Kidd},
year = {2026},
journal = {Annals of Surgery Open},
doi = {10.1097/as9.0000000000000700},
url = {https://doi.org/10.1097/as9.0000000000000700}
}RIS
TY - JOUR TI - Clinical Value of a 51-Neuroendocrine Tumor–Specific Gene Signature (NETest 2.0) for Management of Pancreatic and Small Bowel Neuroendocrine Tumors: A Prospective Study in a Consecutive Cohort of 82 Patients Considered for Surgery AU - Andrea Frilling AU - Ashley Clift AU - Duncan Spalding AU - Panagiotis Drymousis AU - Alexander von Roon AU - Robert Goldin AU - Jamshed Bomanji AU - Harpreet Wasa AU - Abdel B. Halim AU - Mark Kidd PY - 2026 JO - Annals of Surgery Open DO - 10.1097/as9.0000000000000700 UR - https://doi.org/10.1097/as9.0000000000000700 ER -
APA
Frilling, A., Clift, A., Spalding, D., Drymousis, P., Roon, A. V., Goldin, R., Bomanji, J., Wasa, H., Halim, A. B., & Kidd, M. (2026). Clinical Value of a 51-Neuroendocrine Tumor–Specific Gene Signature (NETest 2.0) for Management of Pancreatic and Small Bowel Neuroendocrine Tumors: A Prospective Study in a Consecutive Cohort of 82 Patients Considered for Surgery. Annals of Surgery Open. https://doi.org/10.1097/as9.0000000000000700
Source records
- crossref · retrieved 2026-11-10T19:58:35.477Z